[Form 4] Aptevo Therapeutics Inc Insider Trading Activity
Aptevo Therapeutics reported a compensation-related equity award to Dirk Huebner, the companys SVP and Chief Medical Officer. On 08/06/2025 Mr. Huebner was granted 11,500 Restricted Stock Units (RSUs) that convert on a one-for-one basis into common stock, reflecting a potential issuance of 11,500 shares upon settlement.
The RSUs vest in full on the first anniversary of the grant, so the shares become deliverable only after that one-year vesting period. The filing shows the ownership form as direct and the RSUs carry a $0.00 exercise/conversion price, indicating a straight equity award rather than a purchase-based option.
Aptevo Therapeutics ha comunicato un premio azionario legato alla retribuzione a Dirk Huebner, SVP e Chief Medical Officer della societ脿. Il 08/06/2025 al Sig. Huebner sono state assegnate 11,500 Restricted Stock Units (RSU) convertibili in azioni ordinarie in rapporto uno a uno, con una potenziale emissione di 11,500 azioni al momento del regolamento.
Le RSU maturano per intero al primo anniversario della concessione, pertanto le azioni saranno erogabili solo dopo il periodo di vesting di un anno. Il deposito indica la forma di propriet脿 come diretta e le RSU hanno un prezzo di conversione/esercizio di $0.00, segnalando un award azionario puro piuttosto che un'opzione a pagamento.
Aptevo Therapeutics inform贸 de una concesi贸n de acciones relacionada con la retribuci贸n a Dirk Huebner, SVP y Chief Medical Officer de la compa帽铆a. El 08/06/2025 al Sr. Huebner se le otorgaron 11,500 Restricted Stock Units (RSU) convertibles a raz贸n de una por una en acciones ordinarias, lo que refleja una posible emisi贸n de 11,500 acciones al liquidarse.
Las RSU se consolidan 铆ntegramente en el primer aniversario de la concesi贸n, por lo que las acciones ser谩n entregables solo despu茅s de ese periodo de un a帽o. El registro indica la forma de propiedad como directa y las RSU tienen un precio de conversi贸n/ejercicio de $0.00, lo que apunta a una adjudicaci贸n accionaria pura y no a una opci贸n de compra.
Aptevo Therapeutics電� 氤挫儊 甏�霠� 欤检嫕 氤挫儊 雮挫棴鞚� 須岇偓鞚� SVP 瓴� 斓滉碃鞚橂毂呾瀯鞛�(Chief Medical Officer)鞚� Dirk Huebner鞐愱矊 氤搓碃頄堨姷雼堧嫟. 08/06/2025鞐� Huebner 鞌棎瓴岆姅 11,500 Restricted Stock Units (RSU)臧� 1雽�1 牍勳湪搿� 氤错喌欤茧 鞝勴櫂霅橂弰搿� 攵�鞐悩鞏�, 斓滌 鞝曥偘 鞁� 11,500欤�臧� 氚滍枆霅� 臧�電レ劚鞚� 氚橃榿頃╇媹雼�.
頃措嫻 RSU電� 攵�鞐澕搿滊秬韯� 1雲勳Ц 霅橂姅 雮犾棎 鞝勳暋 氩犾姢韺呺悩鞏�, 1雲勳潣 氩犾姢韺� 旮瓣皠鞚� 歆�雮橃暭毵� 欤检嫕鞚� 歆�旮夒惄雼堧嫟. 鞁犼碃靹滌棎電� 靻岇湢 順曧儨臧� 歆侅爲 氤挫湢(direct)搿� 旮办灛霅橃柎 鞛堨溂氅� RSU鞚� 鞝勴櫂/頄夓偓臧�瓴╈澊 $0.00搿� 響滌嫓霅橃柎 鞛堨柎 毵れ垬順� 鞓奠厴鞚� 鞎勲媽 靾滌垬頃� 欤检嫕 氤挫儊鞛勳潉 雮橅儉雰呺媹雼�.
Aptevo Therapeutics a d茅clar茅 une attribution d'actions li茅e 脿 la r茅mun茅ration 脿 Dirk Huebner, SVP et Directeur M茅dical (Chief Medical Officer) de la soci茅t茅. Le 08/06/2025, M. Huebner s'est vu attribuer 11 500 Restricted Stock Units (RSU) convertibles au taux d'une pour une en actions ordinaires, refl茅tant une 茅mission potentielle de 11 500 actions lors du r猫glement.
Les RSU sont int茅gralement acquises au premier anniversaire de l'attribution, de sorte que les actions ne seront livr茅es qu'apr猫s cette p茅riode d'acquisition d'un an. Le dossier indique la forme de d茅tention comme directe et les RSU pr茅sentent un prix de conversion/exercice de 0,00 $, ce qui indique une attribution d'actions pure plut么t qu'une option d'achat.
Aptevo Therapeutics meldete eine verg眉tungsbezogene Aktienzuteilung an Dirk Huebner, SVP und Chief Medical Officer des Unternehmens. Am 08/06/2025 wurden Herrn Huebner 11.500 Restricted Stock Units (RSUs) gew盲hrt, die im Verh盲ltnis eins zu eins in Stammaktien umgewandelt werden und damit eine potenzielle Ausgabe von 11.500 Aktien bei Abwicklung darstellen.
Die RSUs werden vollst盲ndig am ersten Jahrestag der Gew盲hrung vestet, sodass die Aktien erst nach diesem einj盲hrigen Vesting-Zeitraum auslieferbar sind. Die Einreichung weist die Eigentumsform als direkt aus und die RSUs haben einen Umwandlungs-/Aus眉bungspreis von $0.00, was auf eine reine Aktienzuwendung und nicht auf eine k盲ufliche Option hinweist.
- None.
- None.
Insights
TL;DR: Officer received 11,500 RSUs that vest in one year, aligning management compensation with shareholder outcomes.
The grant of 11,500 RSUs to an executive officer is a routine equity-compensation action intended to tie senior management incentives to equity performance. The units convert one-for-one to common stock and vest in full on the first anniversary, creating a time-based retention incentive. The filing documents the award as direct beneficial ownership, with no cash exercise requirement, which is typical for restricted stock unit awards.
TL;DR: This is a standard time-vested RSU grant: 11,500 shares, one-year cliff vesting, $0 conversion cost.
From a pay-structure perspective, the award is a straightforward retention and alignment tool: 11,500 RSUs that convert 1:1 to common shares and vest in full after one year. The $0 conversion price signals a pure equity grant rather than a purchase option. The materiality of the grant depends on total share count and outstanding equity, which are not provided in this document.
Aptevo Therapeutics ha comunicato un premio azionario legato alla retribuzione a Dirk Huebner, SVP e Chief Medical Officer della societ脿. Il 08/06/2025 al Sig. Huebner sono state assegnate 11,500 Restricted Stock Units (RSU) convertibili in azioni ordinarie in rapporto uno a uno, con una potenziale emissione di 11,500 azioni al momento del regolamento.
Le RSU maturano per intero al primo anniversario della concessione, pertanto le azioni saranno erogabili solo dopo il periodo di vesting di un anno. Il deposito indica la forma di propriet脿 come diretta e le RSU hanno un prezzo di conversione/esercizio di $0.00, segnalando un award azionario puro piuttosto che un'opzione a pagamento.
Aptevo Therapeutics inform贸 de una concesi贸n de acciones relacionada con la retribuci贸n a Dirk Huebner, SVP y Chief Medical Officer de la compa帽铆a. El 08/06/2025 al Sr. Huebner se le otorgaron 11,500 Restricted Stock Units (RSU) convertibles a raz贸n de una por una en acciones ordinarias, lo que refleja una posible emisi贸n de 11,500 acciones al liquidarse.
Las RSU se consolidan 铆ntegramente en el primer aniversario de la concesi贸n, por lo que las acciones ser谩n entregables solo despu茅s de ese periodo de un a帽o. El registro indica la forma de propiedad como directa y las RSU tienen un precio de conversi贸n/ejercicio de $0.00, lo que apunta a una adjudicaci贸n accionaria pura y no a una opci贸n de compra.
Aptevo Therapeutics電� 氤挫儊 甏�霠� 欤检嫕 氤挫儊 雮挫棴鞚� 須岇偓鞚� SVP 瓴� 斓滉碃鞚橂毂呾瀯鞛�(Chief Medical Officer)鞚� Dirk Huebner鞐愱矊 氤搓碃頄堨姷雼堧嫟. 08/06/2025鞐� Huebner 鞌棎瓴岆姅 11,500 Restricted Stock Units (RSU)臧� 1雽�1 牍勳湪搿� 氤错喌欤茧 鞝勴櫂霅橂弰搿� 攵�鞐悩鞏�, 斓滌 鞝曥偘 鞁� 11,500欤�臧� 氚滍枆霅� 臧�電レ劚鞚� 氚橃榿頃╇媹雼�.
頃措嫻 RSU電� 攵�鞐澕搿滊秬韯� 1雲勳Ц 霅橂姅 雮犾棎 鞝勳暋 氩犾姢韺呺悩鞏�, 1雲勳潣 氩犾姢韺� 旮瓣皠鞚� 歆�雮橃暭毵� 欤检嫕鞚� 歆�旮夒惄雼堧嫟. 鞁犼碃靹滌棎電� 靻岇湢 順曧儨臧� 歆侅爲 氤挫湢(direct)搿� 旮办灛霅橃柎 鞛堨溂氅� RSU鞚� 鞝勴櫂/頄夓偓臧�瓴╈澊 $0.00搿� 響滌嫓霅橃柎 鞛堨柎 毵れ垬順� 鞓奠厴鞚� 鞎勲媽 靾滌垬頃� 欤检嫕 氤挫儊鞛勳潉 雮橅儉雰呺媹雼�.
Aptevo Therapeutics a d茅clar茅 une attribution d'actions li茅e 脿 la r茅mun茅ration 脿 Dirk Huebner, SVP et Directeur M茅dical (Chief Medical Officer) de la soci茅t茅. Le 08/06/2025, M. Huebner s'est vu attribuer 11 500 Restricted Stock Units (RSU) convertibles au taux d'une pour une en actions ordinaires, refl茅tant une 茅mission potentielle de 11 500 actions lors du r猫glement.
Les RSU sont int茅gralement acquises au premier anniversaire de l'attribution, de sorte que les actions ne seront livr茅es qu'apr猫s cette p茅riode d'acquisition d'un an. Le dossier indique la forme de d茅tention comme directe et les RSU pr茅sentent un prix de conversion/exercice de 0,00 $, ce qui indique une attribution d'actions pure plut么t qu'une option d'achat.
Aptevo Therapeutics meldete eine verg眉tungsbezogene Aktienzuteilung an Dirk Huebner, SVP und Chief Medical Officer des Unternehmens. Am 08/06/2025 wurden Herrn Huebner 11.500 Restricted Stock Units (RSUs) gew盲hrt, die im Verh盲ltnis eins zu eins in Stammaktien umgewandelt werden und damit eine potenzielle Ausgabe von 11.500 Aktien bei Abwicklung darstellen.
Die RSUs werden vollst盲ndig am ersten Jahrestag der Gew盲hrung vestet, sodass die Aktien erst nach diesem einj盲hrigen Vesting-Zeitraum auslieferbar sind. Die Einreichung weist die Eigentumsform als direkt aus und die RSUs haben einen Umwandlungs-/Aus眉bungspreis von $0.00, was auf eine reine Aktienzuwendung und nicht auf eine k盲ufliche Option hinweist.
FAQ
What did Aptevo (APVO) disclose about Dirk Huebners recent equity award?
When do the RSUs granted to the APVO officer vest?
Does the RSU award to Dirk Huebner require payment to convert into shares?
How many shares will be issued if Dirk Huebners RSUs vest?
What ownership form is reported for the RSUs in the Form 4?
